To this end, bortezomib up-regulates DR4/DR5 expression while reducing cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) levels, thereby effectively overcoming Apo2L/TRAIL resistance in MM cells [16]. This evidence concerns the gene TNFRSF10A and Miyoshi myopathy.